Low rate of RNAemia in blood donations collected during the first wave of COVID-19 in France.
RNAemia
SARS-CoV-2
blood donors
nucleic acid testing
plasma
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
03
01
2022
received:
07
10
2021
accepted:
04
01
2022
pubmed:
29
1
2022
medline:
25
3
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
To investigate the transmission of SARS-CoV-2 via blood, we conducted retrospective molecular screening in blood donated during the first pandemic peak in the two French regions with the highest community transmission. Archived plasma samples randomly selected from donations collected between March 23 and 29, 2020, in Eastern and Northern regions of France were tested for SARS-CoV-2 RNA in minipools of 4 donations (MP4) using the Grifols ProcleixSARS-CoV-2 assay. Reactive MP4 and the four corresponding plasmas were further tested with alternative RT-PCRs and sequencing. Testing for SARS-CoV-2 antibodies and in vitro infectivity in cell culture were also performed. Among the 2818 MP4 (corresponding to 9672 donations) tested for viral RNA, 5 were weakly reactive. Among the 20 plasmas included in these five MP4, one presented low-level reactivity with RT-PCRs and Procleix SARS-CoV-2 and was confirmed on sequencing. The estimated prevalence was 1.03/10,000 (95% CI 0-3.1). The 20 plasmas were antibody nonreactive and none of them showed cytopathic effects in cell culture. When recalled, the index-donor declared having had symptoms compatible with SARS-CoV-2 infection a few days after donation. The two immunocompromised recipients transfused with red blood cells and an inactivated pooled platelet product did not develop COVID-19. Our results indicated a low prevalence of SARS-CoV-2 RNA in the plasma of asymptomatic blood donors during the pandemic peak and no evidence of infectivity in vivo and in vitro. The transfusion risk remains theoretical and does not justify the implementation of SARS-CoV-2 NAT for blood donations.
Sections du résumé
BACKGROUND
To investigate the transmission of SARS-CoV-2 via blood, we conducted retrospective molecular screening in blood donated during the first pandemic peak in the two French regions with the highest community transmission.
METHODS
Archived plasma samples randomly selected from donations collected between March 23 and 29, 2020, in Eastern and Northern regions of France were tested for SARS-CoV-2 RNA in minipools of 4 donations (MP4) using the Grifols ProcleixSARS-CoV-2 assay. Reactive MP4 and the four corresponding plasmas were further tested with alternative RT-PCRs and sequencing. Testing for SARS-CoV-2 antibodies and in vitro infectivity in cell culture were also performed.
RESULTS
Among the 2818 MP4 (corresponding to 9672 donations) tested for viral RNA, 5 were weakly reactive. Among the 20 plasmas included in these five MP4, one presented low-level reactivity with RT-PCRs and Procleix SARS-CoV-2 and was confirmed on sequencing. The estimated prevalence was 1.03/10,000 (95% CI 0-3.1). The 20 plasmas were antibody nonreactive and none of them showed cytopathic effects in cell culture. When recalled, the index-donor declared having had symptoms compatible with SARS-CoV-2 infection a few days after donation. The two immunocompromised recipients transfused with red blood cells and an inactivated pooled platelet product did not develop COVID-19.
CONCLUSION
Our results indicated a low prevalence of SARS-CoV-2 RNA in the plasma of asymptomatic blood donors during the pandemic peak and no evidence of infectivity in vivo and in vitro. The transfusion risk remains theoretical and does not justify the implementation of SARS-CoV-2 NAT for blood donations.
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
633-640Informations de copyright
© 2022 AABB.
Références
Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34:75-80.
Chang L, Zhao L, Gong H, Wang L, Wang L. Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations. Emerg Infect Dis. 2020;26:1631-3.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465-9.
Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20:697-706.
Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect. 2020;9:469-73.
Andersson MI, Arancibia-Carcamo CV, Auckland K, Baillie JK, Barnes E, Beneke T, et al. SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Res. 2020;5:181.
Brendish NJ, Poole S, Naidu VV, Mansbridge CT, Norton N, Borca F, et al. Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: a comparison of patients with and without SARS-CoV-2 infection. J Infect. 2020;81:937-43.
Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020;92:1449-59.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-54.
Rolfes MA, Grijalva CG, Zhu Y, McLean HQ, Hanson KE, Belongia EA, et al. Implications of shortened quarantine among household contacts of index patients with confirmed SARS-CoV-2 infection - Tennessee and Wisconsin, April-September 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1633-7.
Azhar EI, Hindawi SI, El-Kafrawy SA, Hassan AM, Tolah AM, Alandijany TA, et al. Amotosalen and ultraviolet a light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma. Vox Sang. 2021;116:673-81.
Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS One. 2020;15:e0233947.
Hindawi SI, El-Kafrawy SA, Hassan AM, Badawi MA, Bayoumi MM, Almalki AA, et al. Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet a light. Transfus Clin Biol. 2022;29(1):31-36. https://doi.org/10.1016/j.tracli.2021.08.005
Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369:208-11.
Organisation WH. https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2. 2020.
Pastorino B, Touret F, Gilles M, Luciani L, de Lamballerie X, Charrel RN. Evaluation of chemical protocols for inactivating SARS-CoV-2 infectious samples. Viruses. 2020;12(6):624. doi: https://doi.org/10.3390/v12060624.
Nurtop E, Villarroel PMS, Pastorino B, Ninove L, Drexler JF, Roca Y, et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2018;15:192.
Ninove L, Nougairede A, Gazin C, Thirion L, Delogu I, Zandotti C, et al. RNA and DNA bacteriophages as molecular diagnosis controls in clinical virology: a comprehensive study of more than 45,000 routine PCR tests. PLoS One. 2011;6:e16142.
Chaves DG, da Silva Malta MCF, de Souza Madeira Ferreira Boy L, Barbosa AM, Fonseca CN, de Lima Torres DE, et al. Analysis of current SARS-CoV-2 infection in a large population of blood donors evidenced that RNAemia is rare in plasma. Transfusion. 2021;61:2137-45.
Bakkour S, Saa P, Groves JA, Montalvo L, Di Germanio C, Best SM, et al. Minipool testing for SARS-CoV-2 RNA in United States blood donors. Transfusion. 2021;61:2384-91.
Chang L, Yan Y, Zhao L, Hu G, Deng L, Su D, et al. No evidence of SARS-CoV-2 RNA among blood donors: a multicenter study in Hubei, China. Transfusion. 2020;60:2038-46.
Pham TD, Huang C, Wirz OF, Röltgen K, Sahoo MK, Layon A, et al. SARS-CoV-2 RNAemia in a healthy blood donor 40 days after respiratory illness resolution. Ann Intern Med. 2020;173:853-4.
Waheed U, Wazeer A, Saba N, Qasim Z. Detection of severe acute respiratory syndrome coronavirus 2 RNA in blood donations. J Lab Phys. 2020;12:163-4.
Cho HJ, Koo JW, Roh SK, Kim YK, Suh JS, Moon JH, et al. COVID-19 transmission and blood transfusion: a case report. J Infect Public Health. 2020;13:1678-9.
Kwon SY, Kim EJ, Jung YS, Jang JS, Cho NS. Post-donation COVID-19 identification in blood donors. Vox Sang. 2020;115:601-2.
Cappy P, Candotti D, Sauvage V, Lucas Q, Boizeau L, Gomez J, et al. No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation. Blood. 2020;136:1888-91.
Leblanc JF, Germain M, Delage G, O'Brien S, Drews SJ, Lewin A. Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: a literature review. Transfusion. 2020;60:3046-54.
Katz LM. Is SARS-CoV-2 transfusion transmitted? Transfusion. 2020;60:1111-4.
Kiely P, Hoad VC, Seed CR, Gosbell IB. Severe acute respiratory syndrome coronavirus-2: implications for blood safety and sufficiency. Vox Sang. 2021;116:155-66.